Ulf Wiinberg

Ulf Wiinberg is a board member at Alfa Laval and was previously the CEO of Lundbeck from June 2008 to December 2014. Ulf rejuvenated the pipeline and expanded geographies, including the US, to address the steep patent cliff following patent expiries of Lexapro, Cipralex, and Ebixa. Revenue in 2014 was 13.5 billion DKK, +22% since 2008 despite losing approximately 7 billion DKK to generics. The company is now positioned for growth with 6 FDA approved products during Wiinberg's tenure. Key drivers for change have been efficiency programs to create headroom for growth, improved research and development delivery, and successful business development and alliance management with companies such as Otsuka, Takeda, Valeant, Forest, TEVA, Merz.

Previously, Wiinberg was the President of Europe/Middle East/Africa at Wyeth from June 2005 to May 2008. Ulf grew sales from 3 to 6 billion US dollars and Ebit from 1 to 3 billion US dollars by focusing on growth potential for Enbrel and Prevenar, streamlining the other businesses, and eliminating 1500 positions to add 700 new positions thereby creating new capabilities in market access and public affairs and improving quality and compliance in the supply chain.